The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.
about
RASAL3, a novel hematopoietic RasGAP protein, regulates the number and functions of NKT cellsThe mTOR signalling pathway in human cancerTherapeutic Implications of Targeting AKT Signaling in MelanomaSpecific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cellsOther targeted drugs in melanomaPituitary Adenoma and the Chemokine Network: A Systemic ViewVitamins and MelanomaEmerging targeted therapies for melanoma treatment (review)Current and future trials of targeted therapies in cutaneous melanomaStore-operated Ca2+ entry (SOCE) regulates melanoma proliferation and cell migrationEffects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafishIrradiated riboflavin diminishes the aggressiveness of melanoma in vitro and in vivoDecoupling polarization of the Golgi apparatus and GM1 in the plasma membraneA melanoma molecular disease modelHeterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma.Preclinical studies of celastrol and acetyl isogambogic acid in melanoma.Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.Advanced malignant melanoma: immunologic and multimodal therapeutic strategiesMolecular pathogenesis of sporadic melanoma and melanoma-initiating cells.Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesisIL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-RasAssociation between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.Epithelial-mesenchymal-transition-like and TGFβ pathways associated with autochthonous inflammatory melanoma development in miceResistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanomaEpitope-guided engineering of monobody binders for in vivo inhibition of Erk-2 signaling.67-kDa laminin receptor-dependent protein phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance.Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma.Cooperativity of Cdk4R24C and Ras in melanoma development.Activity of the heat shock protein 90 inhibitor ganetespib in melanomaIL-1α expression in pancreatic ductal adenocarcinoma affects the tumor cell migration and is regulated by the p38MAPK signaling pathway.The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsMelatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cellsInhibition of colon cancer cell growth by nanoemulsion carrying gold nanoparticles and lycopene.Phosphoproteomic Analysis of KSHV-Infected Cells Reveals Roles of ORF45-Activated RSK during Lytic ReplicationKinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanomaVS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In VivoMelanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.
P2860
Q24317577-10FC9A10-DC40-4DFC-AE40-E03A7AFF9204Q24627306-D54CD5D5-B1F7-4E41-81E8-0430253321B1Q24631438-3ABD3759-B051-4486-BB98-B51EFEDD2CA2Q24655239-4BDB2F92-4144-4B61-ACD7-D98DDBA54070Q26775594-E7CD9525-E0C7-4EA3-8979-0E255155A6C4Q26781442-72703AA8-6D7F-4A09-8B75-DC4A4952CAE7Q26799314-0D1C51B8-D355-437A-B5D0-84D7C531819AQ26829997-A8EE6BB0-AB9E-464C-829E-14A548D2ED21Q27022355-A9FDB6E2-AB4A-4F1A-8930-745FDB5BD1B3Q27321085-EEA307BF-8A17-4AE2-9E7E-3B3227FA237EQ27852994-D544CA5D-B638-4F25-9674-E1136B411AE1Q28476492-0A1311F7-4682-4CF0-8FAA-AC215592D95EQ28485143-88BC2A86-E4F6-4E80-87A5-2391C91891AFQ28535581-EFD726DC-0446-4EC5-825B-0BF5B6913105Q28741507-02710EDB-D505-4A90-8104-AA42F4B1BD0EQ30317812-E57A4895-562E-4704-B5A9-E8A0083AF49DQ33305774-3DACBBC0-94F8-43D6-96F4-822C753BBD70Q33480990-54F72A0F-C485-49FE-A714-CBF54D5F260FQ33717891-BFE9EC9C-5916-4469-A9FE-3B91887ED991Q33725172-AAED3F55-73C2-44B2-879D-D1FBBBB1A62EQ33825403-824326F7-328E-48A6-A597-0E895F59D912Q34154783-AF748F43-1EE1-4728-B760-CBA1A9BC8F38Q34193764-F53FC918-5384-465B-8D3C-94EE5AABAD85Q34454042-5BDDFBCD-528F-46F8-A40D-AAC73569EC53Q34485253-F80A39E4-C279-4FE6-900D-83AC6F87B095Q34497045-2C2B5768-806C-4396-B8B0-09A692594CABQ34507603-9D1D12AF-A42E-48FA-8D2E-6ACD13F050A9Q34552639-8B9CE5A2-3089-4BDA-BF85-89DE186A7497Q34576062-7B75A24E-6E1F-4216-90DB-FB12DD33CB57Q34583142-7C0F2E89-A329-46DB-9124-FD50DEAEB73BQ34589866-FA8673A2-D165-4E2E-87CA-11CACCEFA593Q34947925-C60515C9-CF0A-48B2-834A-A3B1777D179AQ35037004-577D99D2-7CFA-43B8-A477-758C503CA4ACQ35043887-5D761C6D-F944-4EDB-8357-46DC074E0956Q35125118-AA304451-168C-4A9F-B4BB-42AE35DFC463Q35444840-5A00B1FE-24A5-43AA-80A4-276A596BF393Q35680401-B03162E8-7A19-4E6C-82D8-F6E9F3782D57Q35706499-41AE8037-5A5F-4AB0-8FE9-6C182BC26427Q35708311-D68113A2-F7E7-4447-80CB-D192C5DBA208Q35722779-FCEF98E4-F092-4368-8F10-7CB84EDE6D43
P2860
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The RAS/RAF/MEK/ERK and PI3K/A ...... reatment of advanced melanoma.
@ast
The RAS/RAF/MEK/ERK and PI3K/A ...... reatment of advanced melanoma.
@en
type
label
The RAS/RAF/MEK/ERK and PI3K/A ...... reatment of advanced melanoma.
@ast
The RAS/RAF/MEK/ERK and PI3K/A ...... reatment of advanced melanoma.
@en
prefLabel
The RAS/RAF/MEK/ERK and PI3K/A ...... reatment of advanced melanoma.
@ast
The RAS/RAF/MEK/ERK and PI3K/A ...... reatment of advanced melanoma.
@en
P2093
P356
P1476
The RAS/RAF/MEK/ERK and PI3K/A ...... reatment of advanced melanoma.
@en
P2093
Birgit Schittek
Claus Garbe
Friedegund Meier
Kapaettu Satyamoorthy
Silke Busch
P304
P356
10.2741/1755
P577
2005-09-01T00:00:00Z